U.S. Citigroup, Nike, Tesla
June 20 (Reuters) -Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Citigroup, Nike and Tesla, on Thursday.
HIGHLIGHTS
* Bread Financial Holdings Inc BFH.N: Evercore ISI raises to in line from underperform |
* Citigroup C.N: KBW raises target price to $69 from $66 |
* Lennar Corp LEN.N: Evercore ISI cuts target price to $237 from $238 |
* Nike Inc NKE.N: Barclays cuts target price to $109 from $114 |
* Tesla Inc TSLA.O: RBC cuts target price to $227 from $293 |
Following is a summary of research actions on U.S. companies reported by Reuters on Thursday. Stock entries are in alphabetical order.
* Adma Biologics Inc ADMA.O: Mizuho raises target price to $14 from $12 |
* Agnico Eagle Mines Ltd AEM.N: BMO cuts target price to $77 from $79 |
* Allstate Corp ALL.N: Evercore ISI cuts target price to $178 from $180 |
* Arista Networks Inc ANET.N: BofA Global Research raises PT to $380 from $320 |
* Ball Corp BALL.N: Wells Fargo cuts target price to $64 from $69 |
* Ball Corporation BALL.N: Wells Fargo cuts target price to $64 from $69 |
* Bank of Hawaii Corp BOH.N: Jefferies cuts target price to $53 from $55 |
* Bread Financial Holdings Inc BFH.N: Evercore ISI raises target price to $45 from $42 |
* Bread Financial Holdings Inc BFH.N: Evercore ISI raises to in line from underperform |
* Cardlytics CDLX.O: BofA Global Research reinstates coverage with neutral rating; PT $11 |
* Charles Schwab Corp SCHW.N: Deutsche Bank cuts target price to $81 from $83 |
* Citigroup C.N: KBW raises target price to $69 from $66 |
* Constellation Brands Inc STZ.N: JP Morgan cuts target price to $291 from $296 |
* Constellation Brands Inc STZ.N: UBS cuts target price to $315 from $320 |
* Crocs Inc CROX.O: BofA Global Research raises price objective to $187 from $160 |
* CVS Health CVS.N: Barclays raises target price to $65 from $63 |
* Darden Restaurants Inc DRI.N: Piper Sandler cuts target price to $163 from $167 |
* Delek US Holdings Inc DK.N: Mizuho cuts target price to $27 from $31 |
* Dow Inc DOW.N: Jefferies cuts target price to $55 from $60 |
* Emergent Biosolutions Inc EBS.N: Benchmark raises target price to $8 from $5 |
* Energy Transfer LP ET.N: JP Morgan raises target price to $20 from $19 |
* Enphase Energy Inc ENPH.O: JP Morgan cuts target price to $124 from $128 |
* Esperion Therapeutics ESPR.O: BofA Global Research cuts PT to $2.5 from $2.9 |
* Esperion Therapeutics ESPR.O: BofA Global Research cuts to underperform from neutral |
* Fidelity National Information Services FIS.N: Barclays raises PT to $88 from $85 |
* First Solar FSLR.O: Barclays raises target price to $280 from $228 |
* Freeport-Mcmoran Inc FCX.N: Citigroup raises target price to $52 from $46 |
* General Motors Co GM.N: UBS raises target price to $61 from $58 |
* Healthequity Inc HQY.O: Wells Fargo raises target price to $110 from $107 |
* HF Sinclair Corp DINO.N: Mizuho cuts target price to $61 from $64 |
* Humana HUM.N: Barclays raises target price to $370 from $326 |
* Illumina Inc ILMN.O: Guggenheim cuts target price to $138 from $159 |
* Insmed Inc INSM.O: JP Morgan raises target price to $72 from $55 |
* International Seaways Inc INSW.N: Stifel raises target price to $68 from $66 |
* KB Home KBH.N: Barclays raises target price to $78 from $77 |
* KB Home KBH.N: Evercore ISI raises target price to $86 from $78 |
* KB Home KBH.N: KBW raises target price to $77 from $74 |
* KB Home KBH.N: Wedbush raises target price to $67 from $64 |
* Lennar Corp LEN.N: Barclays cuts target price to $177 from $180 |
* Lennar Corp LEN.N: Barclays cuts target price to $177 from $180 |
* Lennar Corp LEN.N: BofA Global Research cuts price objective to $171 from $189 |
* Lennar Corp LEN.N: BTIG cuts target price to $175 from $177 |
* Lennar Corp LEN.N: Evercore ISI cuts target price to $237 from $238 |
* Lennar Corp LEN.N: JP Morgan cuts target price to $154 from $157 |
* Longboard Pharmaceuticals Inc LBPH.O: Evercore ISI raises PT to $57 from $44 |
* Marathon Petroleum Corp MPC.N: Mizuho cuts target price to $201 from $203 |
* Micron Technology Inc MU.O: Wells Fargo raises target price to $190 from $135 |
* Mirum Pharmaceuticals Inc MIRM.O: Stifel raises target price to $66 from $48 |
* Nextera Energy Inc NEE.N: JP Morgan raises target price to $90 from $76 |
* Nike Inc NKE.N: Barclays cuts target price to $109 from $114 |
* Nike Inc NKE.N: Barclays cuts target price to $109 from $114 |
* Nike Inc NKE.N: Citigroup cuts target price to $115 from $125 |
* Nike Inc NKE.N: JP Morgan cuts target price to $116 from $122 |
* Nvidia NVDA.O: Stifel adjusts PT to $165 from $1140 to reflect 10-for-1 stock split |
* Ocular Therapeutix Inc OCUL.O: TD Cowen raises target price to $11 from $7 |
* Patterson Companies Inc PDCO.O: Morgan Stanley cuts target price to $28 from $30 |
* Paycom Software Inc PAYC.N: TD Cowen cuts target price to $147 from $170 |
* Paycor HCM Inc PYCR.O: TD Cowen cuts target price to $13 from $19 |
* Paylocity Holding Corp PCTY.O: TD Cowen cuts target price to $153 from $180 |
* PBF Energy Inc PBF.N: Mizuho cuts target price to $54 from $58 |
* Phillips 66 PSX.N: Mizuho cuts target price to $160 from $162 |
* Polaris Inc PII.N: BofA Global Research cuts price objective to $86 from $95 |
* Prelude Therapeutics Inc PRLD.O: Barclays cuts to underweight from equal-weight |
* Quaker Houghton KWR.N: Jefferies cuts target price to $185 from $209 |
* Robinhood Markets Inc HOOD.O: Deutsche Bank raises target price to $20 from $19 |
* Sage Therapeutics Inc SAGE.O: JP Morgan cuts target price to $23 from $28 |
* Samsara Inc IOT.N: BofA Global Research initiates coverage with buy rating; PT $37 |
* Shattuck Labs Inc STTK.O: H.C. Wainwright cuts target price to $16 from $28 |
* Southern Copper Corp SCCO.N: Citigroup raises target price to $100 from $73.24 |
* Spirit Aerosystems SPR.N: Benchmark cuts to hold from buy |
* Tesla Inc TSLA.O: RBC cuts target price to $227 from $293 |
* Transdigm Group Inc TDG.N: Deutsche Bank raises target price to $1524 from $1435 |
* TransUnion TRU.N: BofA Global Research raises to buy from neutral |
* Valero Energy Corp VLO.N: Mizuho cuts target price to $171 from $176 |
* Vericel Corp VCEL.O: TD Cowen initiates coverage with buy rating; target price $55 |
* Veris Residential Inc VRE.N: Evercore ISI cuts target price to $16 from $17 |
* Virgin Galactic Holdings SPCE.N: Morgan Stanley raises target price to $35 from $1.75 |
* Virios Therapeutics Inc VIRI.O: Maxim Group initiates coverage with buy rating; PT $1 |
* Zentalis Pharmaceuticals Inc ZNTL.O: Morgan Stanley cuts target price to $8 from $38 |
* Zentalis Pharmaceuticals Inc ZNTL.O: Morgan Stanley cuts to equal-weight |
* Zentalis Pharmaceuticals Inc ZNTL.O: UBS cuts target price to $5 from $28 |
* Zentalis Pharmaceuticals Inc ZNTL.O: UBS cuts to neutral from buy |
* Ziprecruiter Inc ZIP.N: JP Morgan cuts target price to $10 from $12 |
(Compiled by Bengaluru Newsroom)
</body></html>Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
